TICKERNERD
Menu
PSTVPSTVHealthcare · Biotechnology

PSTV Stock Forecast: Plus Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 31 July 2026
$3.87
+6.03% on the day

The 4 Wall Street analysts covering Plus Therapeutics, Inc. hold a median 12-month price target of $38 — +869.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 12 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$26.6M
Ticker Nerd rank
12 / 100
Median analyst target
$38
Analysts covering
4
Total return, dividends reinvested
1W
+1.0%
1M
−7.0%
YTD
−69.6%
1Y
−67.8%
From 52W high
−82.6%
From 52W low
+32.5%
$3
$22
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PSTV stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Plus Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026
12 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
86
Growth
52
Value
40
Revisions
31
Quality
24
Accruals
17
Volatility
16
Momentum
12
Issuance
9

Size (86): Smaller than most of the companies we track.

Issuance (9): The company has been issuing shares or taking on financing, diluting existing holders.

The rank is the raw material. Whether the rules would actually own Plus Therapeutics, Inc. — and when they’d sell — is the membership.

Wall Street

PSTV stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PSTV, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26PSTVHigh $57Median $38Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $12Median $38High $57

The green dot is the last close — the median target sits +869.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
8 June 2026Ascendiant CapitalMaintainsBuy$65 → $57
9 Apr 2026Ascendiant CapitalMaintainsBuy—
31 Mar 2026D. Boral CapitalDowngradeHold—
19 Mar 2026D. Boral CapitalMaintainsBuy—
23 Jan 2026HC Wainwright & Co.MaintainsBuy—
22 Jan 2026D. Boral CapitalMaintainsBuy—
8 Jan 2026D. Boral CapitalMaintainsBuy—
11 Dec 2025D. Boral CapitalMaintainsBuy—
1 Dec 2025D. Boral CapitalMaintainsBuy—
21 Nov 2025Ascendiant CapitalMaintainsBuy—
20 Nov 2025D. Boral CapitalMaintainsBuy—
3 Nov 2025HC Wainwright & Co.MaintainsBuy—
31 Oct 2025D. Boral CapitalMaintainsBuy—
21 Oct 2025D. Boral CapitalMaintainsBuy—
6 Oct 2025Ascendiant CapitalMaintainsBuy—
25 Sept 2025D. Boral CapitalMaintainsBuy—
22 Sept 2025D. Boral CapitalMaintainsBuy—
18 Sept 2025D. Boral CapitalMaintainsBuy—
3 Sept 2025D. Boral CapitalUpgradeBuy—
18 Aug 2025Maxim GroupMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

PSTV analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
2
Fundamentals

Plus Therapeutics, Inc. (PSTV) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.2×

Cheaper than 72% of US stocks

Price / sales
5.1×

Cheaper than 24% of US stocks

Price / book
2.2×

Cheaper than 43% of US stocks

EV / EBITDA
−0.7×

Cheaper than 66% of US stocks

Growth & margins
Revenue growth (YoY)
−2.9%

Higher than 24% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−692.5%

Higher than 7% of US stocks

Net margin
−230.2%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−560.2%

Higher than 2% of US stocks

Return on assets
−73.8%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

PSTV vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PSTVPlus Therapeutics, Inc.$26.6M
12
ALGSAligos Therapeutics, Inc.$26.2M
55
ATNMActinium Pharmaceuticals, Inc.$26.1M
53
KYNBKyntra Bio, Inc.$27.2M
67
ABVCABVC BioPharma, Inc.$25.7M
19
ACTUActuate Therapeutics, Inc.$25.4M
18
IGCIGC Pharma, Inc.$23.9M
6
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PSTV appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest PSTV news & analysis

Cerenome Launches as an Integrated CNS Oncology Company

GlobeNewsWire · 31 July 2026neutral

Plus Therapeutics, Inc. announced that its corporate rebrand to Cerenome will be completed as scheduled, with the name change to Cerenome, Inc. effective August 3, 2026. The company's common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol "CNSY" at market open that day.

Why it matters — PSTV shareholders should note that the stock will trade under a new ticker symbol (CNSY) and the company will operate under a new name (Cerenome, Inc.) starting August 3, 2026.

Plus Therapeutics Announces Scientific Presentations and Sponsored Symposium at 2026 SNO/ASCO CNS Metastases Conference

GlobeNewsWire · 28 July 2026positive

Plus Therapeutics announced that two posters highlighting its ReSPECT-LM clinical development program and CNSide diagnostic platform will be presented at the 2026 SNO/ASCO CNS Metastases Conference, and that the Company and its subsidiary will host a sponsored symposium on redefining the management of leptomeningeal metastases.

Why it matters — A PSTV watcher would care because the presentations and symposium raise the company's visibility in the CNS cancer field and showcase its clinical and diagnostic pipeline at a major industry conference.

FAQ

Frequently asked questions about PSTV stock

What is the PSTV stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Plus Therapeutics, Inc. have a median 12-month price target of $38, with estimates ranging from $12 to $57. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PSTV stock a buy right now?

Of the 4 analysts covering Plus Therapeutics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Plus Therapeutics, Inc. 12 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PSTV?

As at 1 Aug 2026, Plus Therapeutics, Inc. ranks 12 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (86 of 100).

Will PSTV stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +869.0% from the last close, and Ticker Nerd's factor model ranks Plus Therapeutics, Inc. 12 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PSTV stock forecast for 2030?

No analyst covering Plus Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PSTV are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $57 over the next 12 months.

How has PSTV stock performed over the past year?

Plus Therapeutics, Inc. returned -67.8% over the 12 months to 31 July 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Plus Therapeutics, Inc. do?

Plus Therapeutics Inc is a clinical-stage pharmaceutical company specializing in the discovery, development, commercialization, and delivery of complex treatments for patients with cancer and rare diseases. The company concentrates on innovative, targeted radiotherapeutics for adults and children facing difficult-to-treat cancers, utilizing novel drug formulations and technologies to deliver a single, safe, and effective dose of radiation directly to the tumor.

What is the latest news on PSTV?

The most recent item we track (GlobeNewsWire, 31 July 2026): "Cerenome Launches as an Integrated CNS Oncology Company". Plus Therapeutics, Inc. announced that its corporate rebrand to Cerenome will be completed as scheduled, with the name change to Cerenome, Inc. effective August 3, 2026. The company's common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol "CNSY" at market open that day.

Company

About Plus Therapeutics, Inc.

Plus Therapeutics Inc is a clinical-stage pharmaceutical company specializing in the discovery, development, commercialization, and delivery of complex treatments for patients with cancer and rare diseases. The company concentrates on innovative, targeted radiotherapeutics for adults and children facing difficult-to-treat cancers, utilizing novel drug formulations and technologies to deliver a single, safe, and effective dose of radiation directly to the tumor. Its primary programs address recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers, with a key candidate being rhenium (186Re) obisbemeda designed specifically for central nervous system cancers. Operating within the biotechnology sector of healthcare, Plus Therapeutics Inc advances therapies aimed at improving outcomes in oncology and rare disease areas. Headquartered in Houston, Texas, the company focuses on precision medicine approaches to enhance treatment efficacy for challenging medical conditions.

CEO Dr. Marc H. Hedrick M.B.A., M.D. · 28 employees · United States · https://plustherapeutics.com